Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...
Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...
Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug ...
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...
Even though there is no official Ozempic Diet, there are certain foods you can avoid to minimize your chances of negative ...
The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...
The Food and Drug Administration (FDA) last week approved Bristol Myers Squibb’s antipsychotic drug Cobenfy (xanomeline and trospium chloride), the first schizophrenia treatment with an entirely new ...
People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies ...
Zmyra stands out as a potent natural over-the-counter alternative to Ozempic. It provides a comprehensive weight loss ...
A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback